Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment (Q43983859)

28 November 2017

Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment (English)

1 reference

28 November 2017

0 references

0 references

3

1 reference

28 November 2017

Eva Cuchí Burgos

1

0 references

author name string

Montserrat Forné Bardera

series ordinal

2

1 reference

28 November 2017

José Lite Lite

series ordinal

4

1 reference

28 November 2017

Javier Garau Alemany

series ordinal

5

1 reference

28 November 2017

language of work or name

Spanish

0 references

publication date

1 April 2002

1 reference

Infectious Diseases and Clinical Microbiology

28 November 2017

1 reference

28 November 2017

20

1 reference

28 November 2017

4

1 reference

28 November 2017

157-160

1 reference

Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time.

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Stable amoxicillin resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Amoxycillin tolerance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Anti-helicobacter regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective?

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Helicobacter pylori: bacteriology and laboratory diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972778-X

7 January 2021

10.1016/S0213-005X(02)72778-X

Identifiers

DOI

1 reference

28 November 2017

1 reference